138 filings
Page 3 of 7
8-K
3gxh0tsiaplaouv35ee
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
8-K
lbbexj0wrvh
19 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
3ysoh10k lw
7 Jul 22
Departure of Directors or Certain Officers
4:05pm
8-K
rfmbkx65c4by
8 Jun 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ebqec6egtig4isrd
2 Jun 22
Other Events
9:03am
8-K
dt5ea159pux fu5ar
20 May 22
Entry into a Material Definitive Agreement
4:05pm
8-K
ubd2gpnpm137
6 May 22
Entry into a Material Definitive Agreement
6:02am
8-K
ja7ipbo g88k
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
f3d6ncgfd44b w84
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
pz83t
18 Mar 22
Departure of Directors or Certain Officers
6:01am
8-K
n19l3vv73jk
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
1riby7okjjh63ogzj c7
10 Feb 22
Departure of Directors or Certain Officers
9:20am
8-K
5jfkto7hlwtxafop
9 Feb 22
Results of Operations and Financial Condition
4:10pm
8-K
zmu4xago
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
9ap1bwevzer5s4ai
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
clly2aar
16 Nov 21
Departure of Directors or Certain Officers
7:01am
8-K
tkt0ork 9t40be
4 Nov 21
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
7:01am
8-K
3xcgq9og 5atvji
9 Sep 21
Regulation FD Disclosure
7:00am
8-K
cxsrxv
5 Aug 21
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8:30am
8-K
h8vwarbk 0ttwxo
8 Jul 21
Departure of Directors or Certain Officers
8:32am